CAR T therapy for children with B7-H3 solid tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 21 years old or younger
- Have a solid tumor that tests positive for B7-H3 (from a recent tumor biopsy) and have measurable disease you can track
- Have had your cancer return or not respond after standard first treatment
- Be well enough to tolerate treatment (performance score about 50 or higher) and have expected survival longer than 8 weeks
- Have heart, kidney, lung, and blood tests that meet study safety cutoffs (including enough red cells, platelets, and white blood cells, and acceptable oxygen level)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Hear when a new Pediatric Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.